FDA shortage-list compounding rules: 503A and 503B

A drug shortage can change which federal compounding restrictions apply, but it does not make every compounded version lawful or appropriate. FDA explains that some limits on compounding a drug that is essentially a copy of an approved product may not apply while the approved drug is listed on FDA’s Drug Shortages Database. The rules differ for traditional compounding under section 503A and outsourcing facilities under section 503B. Other statutory requirements remain, and compounded drugs are not FDA-approved. Pharmacy technicians should understand the distinction well enough to route questions and records correctly, while the pharmacist or responsible compounder evaluates whether the legal and clinical requirements are satisfied.

Start with the live FDA shortage status

A manufacturer backorder, wholesaler out-of-stock notice, or local inventory gap is not by itself proof that a drug is on FDA’s federal shortage list. FDA maintains a database of current and resolved shortages, discontinuations, and product-specific details. Search the exact active ingredient and dosage form, check the displayed status, and record the date of verification. Similar names, strengths, routes, and presentations can appear separately. Shortage status can change as supply improves or worsens, so a prior screenshot or an old article cannot establish today’s status.

The relevant question is whether the FDA-approved drug product appears on the shortage list under the rule being considered—not simply whether a pharmacy cannot obtain a package today. FDA says it considers supply and demand at the national level. It also notes that local stock problems may be temporary even when no national shortage is listed. For exam scenarios, follow the facts provided; in practice, use FDA’s current database and the organization’s approved process. If the product identity or status is unclear, pause the assumption and ask the pharmacist or compliance contact to confirm it.

How shortage status affects section 503A

Section 503A generally covers compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, subject to federal conditions. One of those conditions restricts compounding products that are essentially copies of commercially available FDA-approved drugs, with limited statutory allowances. FDA says an approved drug is not considered commercially available for this purpose while it appears on the agency’s shortage list. That means the essentially-copy restriction may not apply during the listed shortage circumstance.

This is not a general waiver of 503A. The other conditions still matter, including compounding for an identified individual patient based on a valid prescription, the applicable limits on anticipatory compounding, state pharmacy law, and other restrictions on what may be compounded. A shortage listing does not authorize routine production for general stock without regard to those conditions. Nor does it remove requirements related to the identity and quality of ingredients, labeling, beyond-use dating, recordkeeping, or the pharmacist’s professional responsibilities. The specific facts and the current statute and FDA policy control.

How shortage status affects section 503B

Section 503B applies to FDA-registered outsourcing facilities. These facilities may compound without patient-specific prescriptions in the circumstances allowed by law, but are subject to different conditions, including current good manufacturing practice requirements and FDA oversight. Ordinarily, a 503B facility cannot compound an identical or nearly identical copy of an approved drug. FDA states that this copy restriction does not apply to a copy of an approved drug that is on the shortage list. The facility must still satisfy the remaining 503B conditions.

Bulk drug substances have a separate rule. FDA explains that a 503B facility may generally use a bulk substance only when it appears on the 503B bulks list or when the compounded drug product appears on FDA’s shortage list at the time of compounding, distribution, and dispensing. A shortage exception is therefore tied to the product’s status and the relevant stages; it is not a permanent authorization to use the bulk ingredient after the shortage resolves. Bulk substances must also meet applicable quality requirements, including a valid certificate of analysis, manufacture at an FDA-registered establishment, and compliance with an applicable USP or NF monograph.

A practical comparison

Think of the shortage list as affecting a particular restriction, not replacing the entire legal framework. For a 503A pharmacy, the shortage may affect whether the approved drug is treated as commercially available for the essentially-copy rule, while patient-specific and other 503A conditions remain. For a 503B outsourcing facility, shortage status can affect the copy restriction and may permit use of a bulk substance when the statutory timing condition is met. The facility still must satisfy 503B’s other requirements. In both settings, check the exact product, dosage form, legal pathway, and date; do not transfer a conclusion from one section to the other.

What happens when the shortage is resolved?

When FDA removes an approved drug from the shortage list, the shortage-based basis for the relevant compounding flexibility changes. FDA describes a limited enforcement-discretion policy for certain 503B orders that the facility received while the drug was in shortage. The agency may take action if a facility continues to fill new orders after removal or continues filling existing orders more than 60 days after removal. That 60-day period is described as FDA enforcement policy, not a general statutory grace period or a blanket authorization. Do not apply it automatically to other compounders, products, or situations. Check FDA’s current policy and consult compliance staff.

A resolved status also does not mean that every local supply issue has instantly disappeared. The approved product may still be difficult to source in a particular region, but that fact alone does not restore a federal shortage-based exception. FDA’s national listing and applicable law remain the relevant references for these federal conditions. A pharmacy may have other legally valid paths for an individualized patient need, but the pharmacist must assess them rather than relying on a past shortage listing.

Safety and pharmacy workflow

Compounded drugs can fill a patient-specific need, including when an approved product is unavailable or unsuitable. But FDA does not review compounded drugs for safety, effectiveness, and quality before marketing as it does an approved product. Differences in concentration, formulation, route, packaging, or quality controls may matter. Shortage status does not establish that a compounded product is clinically interchangeable with the FDA-approved drug. The pharmacist and prescriber must make appropriate clinical decisions, and the dispensing organization must follow its law, quality system, and policies.

A technician who receives a question about compounding during a shortage should not decide that the listing authorizes a specific preparation. A sound workflow is to identify the exact drug and formulation; check the current FDA listing through the approved resource; note when it was checked; distinguish the 503A pharmacy from a registered 503B outsourcing facility; and route the question to the pharmacist or compliance lead. Do not substitute an ingredient, compound a copy, or promise availability based on a shortage listing. Preserve the source of the status check and follow organizational rules for purchasing, receiving, and documenting compounded products.

Example and exam checklist

A clinic asks whether a pharmacy can compound an approved injection because a local wholesaler has no stock. First determine whether the exact approved drug is currently on FDA’s shortage list; the wholesaler notice alone is insufficient. Next identify whether the request involves a 503A pharmacy or a 503B outsourcing facility and whether the proposed preparation is an essentially identical copy or uses a bulk substance. The appropriate professional then checks all remaining federal and state requirements, patient-specific facts, and quality controls. If the drug is not listed, the team must not assume the shortage exception applies. If the status recently changed, capture the date and escalate before relying on any transition or enforcement policy.

For the PTCE, remember three points: shortage-list status can affect a copy restriction; 503A and 503B are different legal pathways; and every other applicable condition remains. The list is dynamic, so a historical shortage or local stockout is not enough. Compounded drugs are not FDA-approved, and the technician’s role is to follow the pharmacy’s process and refer legal or clinical determinations to the pharmacist. These distinctions are more reliable than memorizing a list of shortage products that may change.